The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study

References

• Jensen M-B, Ejlertsen B, Mouridsen HT, for the Danish Breast Cancer Cooperative Group, et al. Improvements in breast cancer survival between 1995 and 2012 in Denmark: the importance of earlier diagnosis and adjuvant treatment. Acta Oncol. 2016;55:24–35.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Burstein HJ, Winer EP, on behalf of the Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28:1700–1712.
   PubMed Web of Science ®Google Scholar
• Lumachi F, Luisetto G, Basso SMM, et al. Endocrine therapy of breast cancer. Curr Med Chem. 2011;18:513–522.
   PubMed Web of Science ®Google Scholar
• Dixon JM, Renshaw L, Young O, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26:1671–1676.
   PubMed Web of Science ®Google Scholar
• Rabaglio M, Sun Z, Price KN, et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol. 2009;20:1489–1498.
   PubMed Web of Science ®Google Scholar
• Cooke AL, Metge C, Lix L, et al. Tamoxifen use and osteoporotic fracture risk: a population-based analysis. J Clin Oncol. 2008;26:5227–5232.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353–1361.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
   PubMed Web of Science ®Google Scholar
• Pedersen CB. Description of Danish Registers. The Danish Civil Registration System. Scand J Public Health. 2011;39:22–25.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Amorim LD, Cai J. Modelling recurrent events: a tutorial for analysis in epidemiology. Int J Epidemiol. 2015;44:324–333.
   PubMed Web of Science ®Google Scholar
• Hosmer DW, Lemeshow S, May S. Applied survival analysis. Regression modeling of time-to-event data. 2nd ed. New York: Wiley; 2008.
   Google Scholar
• R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL Available from: https://www.R-project.org/
   Google Scholar
• Therneau TM, Grambsch PM. Modelling survival data: extending the cox model. 2nd ed. New York, NY: Springer; 2000.
   Google Scholar
• Klotzbuecher M, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721–739.
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer. Calcif Tissue Int. 2008;82:334–340.
   PubMed Web of Science ®Google Scholar
• Neuner JM1, Yen TW, Sparapani RA, et al. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. Osteoporosis Int. 2011;22:2847–2855.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717.
   PubMed Web of Science ®Google Scholar
• Svejme O, Ahlborg HG, Nilsson JÅ, et al. Early menopause and risk of osteoporosis, fracture and mortality: a 34-year prospective observational study in 390 women. BJOG. 2012;119:810–816.
   PubMed Web of Science ®Google Scholar
• Koopal C, Janssen-Heijnen ML, van de Wouw AJ, et al. Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer. Breast. 2015;24:153–158.
   PubMed Web of Science ®Google Scholar
• Majumdar SR, Leslie WD, Lix LM, et al. Longer Duration of Diabetes Strongly Impacts Fracture Risk Assessment: The Manitoba BMD Cohort. J Clin Endocrinol Metab. 2016;101:4489–4496.
   PubMed Web of Science ®Google Scholar
• FRAX. Fracture Risk Assessment Tool. Available from: https://www.sheffield.ac.uk/FRAX/index.aspx
   Google Scholar
• Delmas PD, van de Langerijt L, Watts NB, et al. Underdiagnosis of Vertebral Fractures Is a Worldwide Problem: The IMPACT Study. J Bone Miner Res. 2005;20:557–563.
   PubMed Web of Science ®Google Scholar
• Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005;93 (Suppl 1):S16–S22.
   PubMed Web of Science ®Google Scholar
• Kristensen B, Ejlertsen B, Dalgaard P, et al. Tamoxifen and bone metabolism in postmenopausal low risk breast cancer patients: a randomized study. J Clin Oncol. 1994;12:992–997.
   PubMed Web of Science ®Google Scholar